Anúncio
Anúncio

BDTX

BDTX logo

Black Diamond Therapeutics, Inc. Common Stock

2.81
USD
Patrocinado
+0.03
+0.94%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

2.83

+0.02
+0.68%

Relatórios de Lucros BDTX

Rácio de surpresa positiva

BDTX separação 20 de 24 últimas estimativas.

83%

Próximo Relatório

Data do Próximo Relatório
04 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.19
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/
+26.67%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/
-32.14%

Black Diamond Therapeutics, Inc. Common Stock earnings per share and revenue

On 06 de nov. de 2025, BDTX reported earnings of -0.15 USD per share (EPS) for Q3 25, beating the estimate of -0.23 USD, resulting in a 37.32% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +2.84% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 11 analistas forecast an EPS of -0.19 USD, with revenue projected to reach -- USD, implying an aumentar of 26.67% EPS, and aumentar of 0.00% in Revenue from the last quarter.
FAQ
For Q3 2025, Black Diamond Therapeutics, Inc. Common Stock reported EPS of -$0.15, beating estimates by 37.32%, and revenue of $0.00, 0% as expectations.
The stock price moved up 2.84%, changed from $3.87 before the earnings release to $3.98 the day after.
The next earning report is scheduled for 04 de mar. de 2026.
Based on 11 analistas, Black Diamond Therapeutics, Inc. Common Stock is expected to report EPS of -$0.19 and revenue of -- for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio